In Indonesia, breast cancer has the second highest prevalence among all cancer diseases and most of them had Luminal B-Like molecular subtype. There are many factors that promote tumor cells growth such as Topoisomerase II Alpha (TOP2A) and Ki-67. TOP2A is a gene that cuts both strand of the DNA helix to unwind them. This facilitate protein synthesis and DNA replication. The more TOP2A, more replication of the cells which leads to high cells proliferation value. Cell proliferation value can be count with immunohistochemistry, Ki-67 stain. Ki-67 is a protein that is present during all active phases of the cell cycle and absent when the cells are resting. This make Ki-67 is one of the proliferation cells markers. From the literatures, the more TOP2A and Ki-67, the larger the tumor size is. Previous studies said that TOP2A have correlation with Ki-67, but not with tumor size in all subtypes of breast cancer patients. Aim of this study is specifically find the correlation of TOP2A with Ki-67 and tumor size just in one molecular subtype, Luminal B-Like in Indonesian breast cancer patients.
A cross-sectional design study was done and the data was collected from the patients’ medical records in Siloam Hospital Lippo Village within 2014-2018 period. Baseline characteristics were presented using descriptive statistics. Correlation between both variables was analyzed with Spearman correlation.
A total of 141 breast cancer participants from all stages, with age range varied from 20 to 78 years old and 50.19 years old as the mean age (SD = 11.056) were enrolled to this study. Median values of TOP2A, Ki-67 and tumor size respectively are 30% (1%-80%), 70% (4%-95%), and 2 (0.3-30) cm. The expression of TOP2A with Ki-67 have a moderate positive correlation (r = 0.669, p = 0.000). Otherwise, there is no correlation between the expression of TOP2A and Ki-67 with tumor size.
There are correlation between TOP2A with Ki-67 but, there is no correlation with the tumor size. Further study with greater samples is needed to confirm the result.
Clinical trial identification
Legal entity responsible for the study
Pelita Harapan University.
Has not received any funding.
All authors have declared no conflicts of interest.